Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158336 · ClinicalTrials.gov registry record · Phase 1
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
A Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 274
- Enrollment target
NCT04158336: Completed Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
NCT04158336 is a Phase 1 study that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 274 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (357% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04158336, a Phase 1 study, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 274 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Primary Outcome
To investigate the safety and tolerability of single agent ZN-c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), based on the incidence and severity of adverse events (AEs) and dose-limiting toxicities (DLTs) in DLT-evaluable subjects.
Interventions
- DRUG Azenosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 1 |
What the finished NCT04158336 record still lists
NCT04158336 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (357% higher).
The record links to 0 conditions, and to 1 intervention - of which Azenosertib is the first listed.
NCT04158336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04158336 about?
NCT04158336 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors". This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
What is the current status of trial NCT04158336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 274 participants. The study started on 2019-11-01. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT04158336?
The interventions under investigation include: Azenosertib (DRUG).
Who is sponsoring clinical trial NCT04158336?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04158336's enrollment target sits among peer trials
274 149th of 2000 higher than 1,852 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI